Spots Global Cancer Trial Database for paclitaxel for injection (albumin bound)
Every month we try and update this database with for paclitaxel for injection (albumin bound) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. | |
| A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | NCT05193604 | Pancreatic Carc... | TQB2858 injecti... Anlotinib Hydro... Gemcitabine hyd... Paclitaxel for ... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | NCT05193604 | Pancreatic Carc... | TQB2858 injecti... Anlotinib Hydro... Gemcitabine hyd... Paclitaxel for ... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | NCT05193604 | Pancreatic Carc... | TQB2858 injecti... Anlotinib Hydro... Gemcitabine hyd... Paclitaxel for ... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) | NCT04405505 | Triple Negative... | TQB2450 Anlotinib Paclitaxel for ... | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | NCT04506138 | Esophageal Squa... | Camrelizumab Paclitaxel for ... Carboplatin | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | NCT05193604 | Pancreatic Carc... | TQB2858 injecti... Anlotinib Hydro... Gemcitabine hyd... Paclitaxel for ... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | NCT04506138 | Esophageal Squa... | Camrelizumab Paclitaxel for ... Carboplatin | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | NCT06299371 | Non Small Cell ... | Adebrelimab paclitaxel for ... Cisplatin or Ca... | 18 Years - | Liaoning Tumor Hospital & Institute | |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | NCT04506138 | Esophageal Squa... | Camrelizumab Paclitaxel for ... Carboplatin | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
